Therapy and Drug Development
The central nervous system (CNS) drug industry is the second largest therapeutic industry, accounting for a total market value of US $56 billion. With a staggering number of people inflicted with Alzheimer’s, brain injury and other neurodegenerative diseases, there are many companies investigating treatments.
Currently, there is no accurate and objective tool for assessing consciousness; therefore it is impossible to effectively develop drugs and therapies that treat disorders of consciousness.
The HCS has the potential to be used as a screening solution for proper selection of controls in hard to diagnose neurologic indications, such as the differentiation of depression from dementia and to be used for following the course of dementing diseases and treatments to evaluate efficacy of therapies that are under development. There is a great opportunity to significantly reduce the overall cost of trials and improve the quality of the therapies.